Revolution Medicines SVP & General Counsel Jeff Cislini Sells $670K in Shares for Tax Withholding
Revolution Medicines, Inc.
Subscribe to track RVMD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
### Insider Transaction: Revolution Medicines, Inc. ($RVMD)
**Insider:** Jeff Cislini (SVP & General Counsel)
**Transaction:** Sale of 3,366 shares at ~$199.24 ($670,631 total)
**Date:** 2026-09-16
**Nature:** Direct | Rule 10b5-1 Tax Withholding
**Post-Transaction Holdings:** 52,541 shares
**Significance:** Low (Routine sell-to-cover for RSU vesting taxes)
Comprehensive Analysis
Executive Summary
On September 16, 2026, Jeff Cislini, SVP & General Counsel of Revolution Medicines, Inc. ($RVMD), executed two open-market sales totaling 3,366 shares of Common Stock. The shares were sold at a weighted average price of approximately $199.24 per share, resulting in gross proceeds of $670,631.26. Following these transactions, Cislini directly retains 52,541 shares of common stock, which includes 37,088 unvested restricted stock units (RSUs).
Transaction Breakdown
- Batch 1: 52 shares sold at a weighted average price of $195.0087 (ranging from $195.00 to $195.03).
- Batch 2: 3,314 shares sold at a price of $199.3032.
- Aggregate Disposed: 3,366 shares for $670,631.26.
Context and Intent
Footnotes indicate the transactions were executed pursuant to a pre-arranged Rule 10b5-1 instruction letter adopted on May 31, 2023. The sales were carried out specifically to cover tax withholding obligations associated with the vesting of restricted stock units. Because this is an automated "sell-to-cover" transaction driven by tax compliance rather than discretionary market timing, it conveys low informational signal regarding executive sentiment or business outlook.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.